Rare diseases have a lot to gain from greater awareness
It is important to raise awareness of rare diseases in the country for various reasons. First, doctors may never have encountered them and are often unaware of these diseases. Second, if the medical problem is not reported, say to a registry, an accurate picture of the number of patients is unavailable, which would be essential to help draft suitable policies to support patients. A detailed picture is also needed to help patients connect with each other, and so that industry identifies market opportunities to develop suitable therapies.
In a major contribution to identifying rare diseases, Iliyas Rashid and his team at the Tata Institute for Genetics and Society, Bengaluru, have developed GenTIGS, 'a gene database on rare genetic disorders'. This is a valuable resource, since a user can choose from a list of symptoms to predict the possible rare disease. The patient's family can then take the information to their doctor and seek support from a patient group.
So far, fewer than 5% of rare diseases have treatments approved by the U.S. Food and Drug Administration. Even those that have are prohibitively expensive. A patient in India would be unlikely to have suitable insurance coverage. Sometimes companies provide a drug for free on compassionate grounds, but this is not a reliable way of obtaining drugs. Some have managed to raise the money through crowd sourcing.
Of the 300 million people with rare diseases in the world, about 90 million are in India. But the real number is likely to be higher since our social practices include endogamy, the practice of marrying within a community. If there is a genetic condition in that community, endogamous marriages will tend to preserve that condition instead of letting it die out.
More than 95% of these conditions don't have a therapy or it may be impossibly expensive. In such a scenario, the best option may be premarital counselling, among others. There are now cases where scientists, doctors or not-for-profit organisations have worked with local communities to urge individuals who are carriers of particular mutations to not marry other individuals with the same mutations, in case this would increase the chance of their having an affected child.
If such marriages are avoided, then over time the condition will be eliminated. In this connection, exemplary work has been done by B.R. Lakshmi and her colleagues at the Molecular Diagnostics Counselling Care and Research Centre (MDCRC) in Coimbatore. They are working on Duchenne muscular dystrophy (DMD), a disorder that affects only male children, with females being the carriers. MDCRC has done large-scale genetic screening across several districts of Tamil Nadu with the aim of detecting the relevant mutations early and eventually eradicating DMD from the State. Similar efforts are required for many disorders around the country.
In summary, be aware of rare diseases. It usually takes years for a patient to get the correct diagnosis. Dr. Rashid's database ought to be helpful in reducing the suffering of patients and their families.
Gayatri Saberwal is a consultant at the Tata Institute for Genetics and Society.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
a day ago
- The Hindu
Lupin gets U.S. FDA nod for two generic diabetes drugs
Generic drugmaker Lupin has received U.S. Food and Drug Administration approval for its abbreviated new drug applications for Liraglutide Injection single-patient-use prefilled pens and Glucagon for injection vials. Both the products will be manufactured at the company's injectable facility in Nagpur, Lupin said. Liraglutide injection 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pen is bioequivalent to Novo Nordisk's Victoza injection and had an estimated annual sale of $458 million in the U.S, the company said citing IQVIA MAT May numbers. The drug is indicated to improve glycaemic control in adults and children, aged above 10 years, with type 2 diabetes mellitus. Glucagon for Injection USP, 1 mg/vial, is bioequivalent to Eli Lilly and Company's Glucagon for Injection, 1 mg/vial. It is indicated for treatment of severe hypoglycaemia in paediatric and adult patients with diabetes mellitus and as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients. It had an estimated annual sale of $124 million in the U.S. Chief Scientific Officer Shahin Fesharaki said the two products are a meaningful enhancement to the company's portfolio.
India Today
4 days ago
- India Today
Elon Musk says Neuralink brain implants could help millions reclaim lost abilities after double surgery success
Neuralink, the brain-computer interface company co-founded by Elon Musk, has once again announced successful surgeries, this time having successfully conducted two brain implant operations in a single day. The company revealed that both patients are recovering well. Elon Musk responded swiftly to the achievement and expressed his optimism about the technology's potential impact in the near the announcement of Neuralink, Musk wrote on X (formally Twitter) "Neuralink will do life-changing good for ultimately millions, maybe billions, of people. Imagine your loved one being able to walk again or your parent with dementia being able to recognise their child again." advertisementNeuralink conducted its first successful implantation in a human patient, 30-year-old Noland Arbaugh, in March 2024. Following the surgery, Arbaugh, who is paralysed from the shoulders down, was able to control a computer cursor and play chess using only his thoughts. With his successful surgery the company highlighted the capabilities of the Link in helping patients improve their living. What is the Neuralink brain chip? Neuralink's device, known as "the Link," is a brain-computer interface (BCI) designed to interpret neural activity and transmit it to external devices. This coin-sized implant is inserted directly into the skull, with ultra-thin threads embedded in the cerebral cortex. These threads are equipped with 1,024 electrodes which monitor brain signals. The data collected by these threads is then processed by a custom chip and sent wirelessly to connected devices via Neuralink performs this surgical process using a robotic surgical system developed by the company. Musk once noted that these robots are capable of inserting the electrodes with a precision far beyond human capability. The surgical robot ensures the threads are placed with minimal tissue damage and maximum primary aim of the Link is to restore basic abilities lost due to neurological damage. Initially, Neuralink is focused on assisting people with severe paralysis to regain control over digital devices, prosthetics, or communication systems through thought alone. By decoding neural signals and transmitting them back into the brain or other devices, the chip enables users to interact with technology in real-time, the future, Elon Musk has suggested that Neuralink could, in time, help treat a wide range of conditions, from spinal injuries and blindness to dementia and Neuralink's trials have received approval from the U.S. Food and Drug Administration (FDA), the specifics of trial locations, long-term safety data, and performance metrics remain largely undisclosed. The limited public data, and the absence of registration with key clinical trial databases have raised ethical questions about transparency and regulatory compliance.- Ends
The Hindu
6 days ago
- The Hindu
Rare diseases have a lot to gain from greater awareness
About 10,000 rare diseases have thus far been identified in the world, and new ones are discovered every now and then. Some 80% of these conditions are genetic in origin and predominantly affect children. About 30% of the children don't live to see their fifth birthday. While individually rare, cumulatively about 300 million people in the world have a rare disease. It is important to raise awareness of rare diseases in the country for various reasons. First, doctors may never have encountered them and are often unaware of these diseases. Second, if the medical problem is not reported, say to a registry, an accurate picture of the number of patients is unavailable, which would be essential to help draft suitable policies to support patients. A detailed picture is also needed to help patients connect with each other, and so that industry identifies market opportunities to develop suitable therapies. In a major contribution to identifying rare diseases, Iliyas Rashid and his team at the Tata Institute for Genetics and Society, Bengaluru, have developed GenTIGS, 'a gene database on rare genetic disorders'. This is a valuable resource, since a user can choose from a list of symptoms to predict the possible rare disease. The patient's family can then take the information to their doctor and seek support from a patient group. So far, fewer than 5% of rare diseases have treatments approved by the U.S. Food and Drug Administration. Even those that have are prohibitively expensive. A patient in India would be unlikely to have suitable insurance coverage. Sometimes companies provide a drug for free on compassionate grounds, but this is not a reliable way of obtaining drugs. Some have managed to raise the money through crowd sourcing. Of the 300 million people with rare diseases in the world, about 90 million are in India. But the real number is likely to be higher since our social practices include endogamy, the practice of marrying within a community. If there is a genetic condition in that community, endogamous marriages will tend to preserve that condition instead of letting it die out. More than 95% of these conditions don't have a therapy or it may be impossibly expensive. In such a scenario, the best option may be premarital counselling, among others. There are now cases where scientists, doctors or not-for-profit organisations have worked with local communities to urge individuals who are carriers of particular mutations to not marry other individuals with the same mutations, in case this would increase the chance of their having an affected child. If such marriages are avoided, then over time the condition will be eliminated. In this connection, exemplary work has been done by B.R. Lakshmi and her colleagues at the Molecular Diagnostics Counselling Care and Research Centre (MDCRC) in Coimbatore. They are working on Duchenne muscular dystrophy (DMD), a disorder that affects only male children, with females being the carriers. MDCRC has done large-scale genetic screening across several districts of Tamil Nadu with the aim of detecting the relevant mutations early and eventually eradicating DMD from the State. Similar efforts are required for many disorders around the country. In summary, be aware of rare diseases. It usually takes years for a patient to get the correct diagnosis. Dr. Rashid's database ought to be helpful in reducing the suffering of patients and their families. Gayatri Saberwal is a consultant at the Tata Institute for Genetics and Society.
